Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

25 years of biologic DMARDs in rheumatology.

Feldmann M. et al, (2023), Nat rev rheumatol

Identifying collagen VI as a target of fibrotic diseases regulated by CREBBP/EP300.

Williams LM. et al, (2020), Proc natl acad sci u s a, 117, 20753 - 20763

Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed.

Feldmann M. et al, (2020), Lancet, 395, 1407 - 1409

Developments in therapy with monoclonal antibodies and related proteins.

Shepard HM. et al, (2017), Clin med (lond), 17, 220 - 232

Anti-TNF Therapy.

Udalova I. et al, (2016), Microbiol spectr, 4

Macrophage heterogeneity in the context of rheumatoid arthritis.

Udalova IA. et al, (2016), Nat rev rheumatol, 12, 472 - 485

IRF5 controls both acute and chronic inflammation

Weiss M. et al, (2015), Proceedings of the national academy of sciences of the united states of america, 112, 11001 - 11006

IRF5 controls both acute and chronic inflammation.

Weiss M. et al, (2015), Proc natl acad sci u s a, 112, 11001 - 11006

Preclinical target validation using patient-derived cells.

Edwards AM. et al, (2015), Nat rev drug discov, 14, 149 - 150

Load More